Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
To date, all the major clinical trials of vaccines against COVID-19 have been in adults.
Dyno will be responsible for the design of the novel AAV capsids that are expected to have improved functional properties for gene therapy. Roche and its subsidiary Spark Therapeutics will take the capsids and conduct preclinical studies with hopes of taking them into the clinic, and eventually to commercialization.
Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the Tokyo-based pharmaceutical company in moving 80% of its applications to the “cloud” and modernizing the company’s research tools.
The urgency of 2020 has shone a spotlight on the investment and advances in the U.S. biotech industry over the past decade – and overall, it is looking strong.
Femtech represents significant growth opportunities for biotech companies, but is still under the radar for most investors. None-the-less, pioneering companies are emerging to address this sector’s many underserved needs.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
Charles M. Lieber is currently on paid leave from Harvard’s chemistry department after his arrest in January on charges of lying to the U.S. government about funds received from China.
A 41-year-old man from Richland, Wash. was convicted on 47 counts of fraud and drug related charges on Oct. 1, according to the U.S. Justice Department’s Eastern District of Washington.
New 50,000-square-foot facility will allow them to expand their services from development and Phase I/II to Phase III and manufacturing.
Results from multiple Phase III trials show consistent improvements in pain relief and physical function.